SG Americas Securities LLC boosted its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 36.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,452 shares of the company’s stock after purchasing an additional 4,626 shares during the quarter. SG Americas Securities LLC owned 0.06% of Fulgent Genetics worth $379,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of FLGT. Asset Dedication LLC bought a new stake in shares of Fulgent Genetics in the second quarter worth about $33,000. nVerses Capital LLC acquired a new position in shares of Fulgent Genetics in the 2nd quarter valued at approximately $43,000. Signaturefd LLC increased its stake in Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after purchasing an additional 1,132 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Fulgent Genetics during the 2nd quarter worth approximately $63,000. Finally, State Board of Administration of Florida Retirement System bought a new position in Fulgent Genetics in the first quarter valued at approximately $178,000. Institutional investors own 48.06% of the company’s stock.
Fulgent Genetics Stock Up 0.5 %
Shares of FLGT stock opened at $19.76 on Friday. Fulgent Genetics, Inc. has a 12-month low of $18.91 and a 12-month high of $30.68. The firm has a fifty day moving average of $21.86 and a 200-day moving average of $21.48. The company has a market capitalization of $591.30 million, a price-to-earnings ratio of -3.55 and a beta of 1.50.
Insider Buying and Selling
In other Fulgent Genetics news, CEO Ming Hsieh sold 2,313 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total value of $52,805.79. Following the sale, the chief executive officer now owns 707,275 shares in the company, valued at approximately $16,147,088.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 4,324 shares of company stock worth $98,717. 31.76% of the stock is owned by corporate insiders.
About Fulgent Genetics
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Further Reading
- Five stocks we like better than Fulgent Genetics
- Profitably Trade Stocks at 52-Week Highs
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Election Stocks: How Elections Affect the Stock Market
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Invest in Insurance Companies: A Guide
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.